ArticleMaterials today. Bio2025
Sorafenib-loaded metal-organic framework nanoparticles for anti-hepatocellular carcinoma effects through synergistically potentiating ferroptosis and remodeling tumor immune microenvironment.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Magnetic nanorobots in oncology: From targeted drug delivery to smart theranostic systems.Materials today. Bio · 2026Review
- Targeting ferroptosis induction via nanomaterials in hepatocellular carcinoma: an insight into mechanism and therapeutic potential.Journal of nanobiotechnology · 2026Review
- "Ferroptosis-immune" cycle: Research progress of tumor microenvironment responsive nanomaterials in the treatment of pancreatic cancer.iScience · 2026Review
- Microfluidic Encapsulation of Sorafenib-Loaded ZIF-8 Nanoparticles in pH-Responsive Alginate Microparticles for Oral Chemotherapy of Hepatocellular Carcinoma.ACS applied bio materials · 2026Article
- Ferroptosis-centered strategies: redefining therapeutic resistance & adaptation in modern oncology.Apoptosis : an international journal on programmed cell death · 2026Review
- Post-Translational Modification Networks in Ferroptosis: Orchestrating Defense, Drug Resistance, and Therapeutic Opportunities in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Review
- Radiographic evidence of thymic involution in hepatocellular carcinoma: a propensity score-matched study in viral cirrhosis.Frontiers in immunology · 2026Article
- Ferroptosis reshapes the tumor immune microenvironment: molecular mechanisms, immune regulation, and therapeutic synergistic strategies.Frontiers in immunology · 2026Review
- Recent advances in drug repurposing for cancer immunomodulation emerging strategies, mechanistic insights, and clinical translation.Frontiers in oncology · 2026Review
- Metal-organic frameworks-mediated reactive oxygen species modulation in the tumor microenvironment of digestive system malignancies: latest advances.Frontiers in chemistry · 2026Review
- Construction of a severity prediction model for hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease based on machine learning.European journal of medical research · 2025Article
- Biomimetic selenium nanomedicine with homologous targeting enhances hepatocellular carcinoma therapy.Materials today. Bio · 2025Article
- The Immune Microenvironment in Liver Cancer: From Analysis to Targeting.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Targeting ferroptosis and cuproptosis in gastrointestinal cancers: molecular mechanisms, metabolic vulnerabilities, and therapeutic interventions.Molecular biomedicine · 2025Review
- Exosomal crosstalk: the metastatic language of hepatocellular carcinoma.Frontiers in immunology · 2025Review
- Iron-fueled ferroptosis: a new axis for immunomodulation to overcome cancer drug resistance-from immune microenvironment crosstalk to therapeutic translation.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sorafenib (Sor), a multi-kinase inhibitor, serves as the first-line systemic therapeutic drug for advanced hepatocellular carcinoma (HCC). Unfortunately, clinical benefit was confirmed in only a minority of patients, limiting clinical application of Sor. Using nanotechnology to enhance the therapeutic effect of anti-cancer drugs has become a major trend. Accordingly, a Fe(III)-based metal-organic framework (MOF) nanocarrier encapsulating Sor (Sor@Fe-MOF) with ferroptosis/immune activation functions was constructed for HCC therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.